Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The **capsid protein of Enterovirus D68 (EV-D68)** comprises an icosahedral shell encapsulating the viral RNA genome, formed by 60 copies each of the structural proteins **VP1, VP2, VP3**, and **VP4**[6][7][10]. These proteins assemble into protomers (VP1-VP4), further forming the mature viral capsid (about 30 nm diameter)[1][4]. The outer surface is composed mainly of VP1–VP3, with a unique canyon structure surrounding the fivefold axes that serves as a primary site for host receptor binding (notably **sialic acid** and **ICAM-5**)[1][2]. VP4 is internal, associated with the capsid interior and genome. The capsid undergoes conformational changes upon receptor binding or acidification, facilitating viral uncoating and genome release[1][7]. This protein complex is considered a therapeutic target for antivirals such as pleconaril (which binds to and stabilizes the capsid, blocking uncoating) and for neutralizing antibodies that block receptor engagement or induce premature uncoating[10][1]. The capsid is also a key antigenic target for vaccine development and host immune responses against EV-D68; changes in capsid structure or sequence may influence viral pathogenesis, immune escape, and resistance to therapy.
Inhibition of viral attachment to host receptors by blocking the canyon or other capsid sites[1][3] Stabilization of the capsid to prevent conformational transitions required for uncoating[10] Premature triggering of uncoating transitions leading to noninfectious particles
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Capsid protein of Enterovirus D68.